Author Archives: Vijaya Iyer, PhD

ContraFect Granted Up to $6.94M to Develop Novel Therapy Against ESKAPE Pathogens

ContraFect will receive up to $6.94 million in funding from CARB-X to support the development of their proprietary therapeutic peptides — amurins — against antibiotic-resistant bacterial infections caused by gram-negative ESKAPE pathogens. The company intends to develop these compounds as potential therapies for pulmonary exacerbations of cystic fibrosis and hospital-acquired…

Featured Column

The Benefits of Being Sick

A banner for Lara's column, depicting a car on a road trip winding through a forest.
As columnist Lara Govendo reflects on her journey through CF and transplant, she realizes there are a surprising number of benefits.

Read the Column

Your CF Community

Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.